Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
79.04
+1.30 (1.67%)
At close: May 12, 2026, 4:00 PM EDT
78.18
-0.86 (-1.09%)
After-hours: May 12, 2026, 7:58 PM EDT
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
| Name | Position |
|---|---|
| Aaron Tan | Head of Tax |
| Dr. Bruce D. Given M.D. | Chief Medical Scientist |
| Dr. Christopher R. Anzalone Ph.D. | Chairman, CEO & President |
| Dr. James C. Hamilton M.D., MBA | Chief Medical Officer and Head of R&D |
| Dr. Mark Seefeld | Head of Toxicology & VP |
| Dr. Mark M. Davis Ph.D. | Founder and Founder & Director of Insert Therapeutics Inc & Calando |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | S-8 | d30467ds8.htm |
| 2026-03-20 | 8-K | arwr-20260319.htm |
| 2026-02-05 | 8-K | arwr-20260205.htm |
| 2026-01-27 | DEFA14A | noiticeandfilingtext.htm |
| 2026-01-12 | 8-K | d19865d8k.htm |
| 2026-01-09 | 8-K | d94918d8k.htm |
| 2026-01-08 | 305B2 | d874243d305b2.htm |
| 2026-01-06 | 8-K | arwr-20260106.htm |
| 2025-12-11 | S-3ASR | d16145ds3asr.htm |
| 2025-11-25 | 10-K | arwr-20250930.htm |
| Dr. Tao Pei Ph.D. | Chief Scientific Officer |
| Dr. Vincent Anzalone CFA | Head of Investor Relations & VP |
| Mr. Daniel J. Apel | Chief Financial Officer |
| Mr. Howard Lovy | Director of Communications |